Practical guidance for echocardiography for cancer therapy-related cardiac dysfunction: 2026 focused update
Journal of Echocardiography · 2026
DOI: 10.1007/s12574-026-00731-4 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Echocardiography, 2026. Verfasst von Hidekazu Tanaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Kindai University Faculty of Medicine, Osaka, Japan. tanakah@med.kindai.ac.jp. Hauptthemen laut MEDLINE: Neoplasms, Echocardiography, Cardiotoxicity, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cancer therapy–related cardiac dysfunction (CTRCD) has become an important clinical issue with advances in cancer treatment and improved patient survival. The Japanese Society of Echocardiography previously published practice guidance in 2020. The present document provides an updated revision reflecting recent developments in cardio-oncology.
Methods
This guidance was developed based on contemporary evidence, including the 2022 European Society of Cardiology cardio-oncology guidelines, recent clinical studies, and advances in echocardiographic and multimodality imaging technologies.
Results
Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) are emphasized as essential parameters for diagnosing and monitoring CTRCD. The document provides standardized protocols for echocardiographic evaluation before, during, and after cancer drug therapy, as well as recommendations for long-term surveillance following radiotherapy. It also addresses cardiovascular complications associated with immune checkpoint inhibitors, particularly myocarditis, and highlights the importance of measurement accuracy, quality control, artificial intelligence, and three-dimensional echocardiography in clinical practice.
Conclusions
This updated guidance offers practical and evidence-based recommendations for echocardiographic assessment in cardio-oncology, aiming to facilitate early detection of cardiotoxicity and optimize multidisciplinary management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Kindai University Faculty of Medicine, Osaka, Japan. tanakah@med.kindai.ac.jp.
- Department of Onco-Cardiology/Cardiovascular Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Community Medicine for Cardiology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
- Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Cardiology, Tenri Hospital, Tenri, Japan.
- Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Zitieren
APA
Tanaka, H., Fukuda, Y., Yamada, H., Miyazaki, S., Sakamoto, J., Daimon, M., & Guideline Committee of the Japanese Society of Echocardiography (2026). Practical guidance for echocardiography for cancer therapy-related cardiac dysfunction: 2026 focused update. Journal of Echocardiography. https://doi.org/10.1007/s12574-026-00731-4
Vancouver
Tanaka H, Fukuda Y, Yamada H, Miyazaki S, Sakamoto J, Daimon M, et al. Practical guidance for echocardiography for cancer therapy-related cardiac dysfunction: 2026 focused update. Journal of Echocardiography. 2026. doi:10.1007/s12574-026-00731-4
BibTeX
@article{Tanaka2026,
author = {Tanaka, Hidekazu and Fukuda, Yuko and Yamada, Hirotsugu and Miyazaki, Sakiko and Sakamoto, Jiro and Daimon, Masao and Guideline Committee of the Japanese Society of Echocardiography, Guideline Committee of the Japanese Society of Echocardiography},
title = {Practical guidance for echocardiography for cancer therapy-related cardiac dysfunction: 2026 focused update},
journal = {Journal of Echocardiography},
year = {2026},
doi = {10.1007/s12574-026-00731-4}
}
EUVIMED